2.71
price down icon2.52%   -0.07
after-market アフターアワーズ: 3.43 0.72 +26.57%
loading
前日終値:
$2.78
開ける:
$2.77
24時間の取引高:
1.02M
Relative Volume:
0.42
時価総額:
$63.92M
収益:
$155.00K
当期純損益:
$-30.01M
株価収益率:
-1.6228
EPS:
-1.67
ネットキャッシュフロー:
$-11.98M
1週間 パフォーマンス:
+11.98%
1か月 パフォーマンス:
-63.23%
6か月 パフォーマンス:
-67.97%
1年 パフォーマンス:
-68.00%
1日の値動き範囲:
Value
$2.615
$2.83
1週間の範囲:
Value
$2.27
$3.00
52週間の値動き範囲:
Value
$1.89
$11.64

Inmune Bio Inc Stock (INMB) Company Profile

Name
名前
Inmune Bio Inc
Name
セクター
Healthcare (1164)
Name
電話
(858) 964-3720
Name
住所
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Name
職員
13
Name
Twitter
@INmuneBio
Name
次回の収益日
2025-05-02
Name
最新のSEC提出書
Name
INMB's Discussions on Twitter

INMB を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
INMB
Inmune Bio Inc
2.71 75.73M 155.00K -30.01M -11.98M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-01 ダウングレード BTIG Research Buy → Neutral
2025-07-01 ダウングレード Scotiabank Sector Outperform → Sector Underperform
2025-01-28 開始されました Rodman & Renshaw Buy
2024-10-21 開始されました Alliance Global Partners Buy
2024-09-27 開始されました Raymond James Outperform
2024-08-22 開始されました Scotiabank Sector Outperform
2023-06-01 開始されました Robert W. Baird Outperform
2022-05-24 ダウングレード B. Riley Securities Buy → Neutral
2021-07-07 繰り返されました Maxim Group Buy
2021-04-21 開始されました B. Riley Securities Buy
2021-01-22 繰り返されました Maxim Group Buy
2020-09-01 開始されました BTIG Research Buy
2020-07-15 繰り返されました H.C. Wainwright Buy
すべてを表示

Inmune Bio Inc (INMB) 最新ニュース

pulisher
Jul 25, 2025

Inmune Bio Reveals Promising XPro™ Trial Results - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Is INmune Bio Inc. a good long term investmentOutstanding capital growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about INmune Bio Inc. stockOutstanding yields - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at - GuruFocus

Jul 25, 2025
pulisher
Jul 24, 2025

INmune Bio Inc. Stock Analysis and ForecastSuperior risk-adjusted returns - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

INmune Bio announces analyses from Phase 2 MINDFuL trial, endpoint not met - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference - The Manila Times

Jul 24, 2025
pulisher
Jul 24, 2025

INmune Bio to present additional Phase 2 Alzheimer’s trial data - Investing.com Australia

Jul 24, 2025
pulisher
Jul 23, 2025

Is INMB more suitable for short-term or long-term investment? - AInvest

Jul 23, 2025
pulisher
Jul 22, 2025

When (INMB) Moves Investors should Listen - news.stocktradersdaily.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives INmune Bio Inc. stock priceRapid wealth accumulation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

Is INmune Bio Inc. stock overhyped or has real potentialFree Stock Selection with 300% Return - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

Why INmune Bio Inc. stock attracts strong analyst attentionInsider Strategy Insight - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How INmune Bio Inc. stock performs during market volatilityCapital Growth Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Cambridge Investment Research Advisors Inc. Makes New $180,000 Investment in INmune Bio, Inc. (NASDAQ:INMB) - Defense World

Jul 15, 2025
pulisher
Jul 15, 2025

What makes INmune Bio Inc. stock price move sharplyTop Momentum Stock Pick - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

INmune Bio Shares Collapse After Mixed Results from Alzheimer’s Drug Trial - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

Where are the Opportunities in (INMB) - news.stocktradersdaily.com

Jul 12, 2025
pulisher
Jul 07, 2025

INmune Bio shares slide after Phase II Alzheimer’s trial misses endpoints - MSN

Jul 07, 2025
pulisher
Jul 06, 2025

INmune Bio reverses early gains after stock offering - MSN

Jul 06, 2025
pulisher
Jul 06, 2025

INmune Bio surges ahead of mid-stage trial readout for Alzheimer’s drug - MSN

Jul 06, 2025
pulisher
Jul 05, 2025

INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record low - MSN

Jul 05, 2025
pulisher
Jul 04, 2025

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday - Benzinga

Jul 04, 2025
pulisher
Jul 03, 2025

INmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumble - MSN

Jul 03, 2025
pulisher
Jul 02, 2025

XPro™'s Subgroup Success: A Silver Lining in INmune Bio's Alzheimer's Setback - AInvest

Jul 02, 2025
pulisher
Jul 02, 2025

INmune Bio's $19M Funding: A Lifeline or a Launchpad for Breakthroughs? - AInvest

Jul 02, 2025
pulisher
Jul 01, 2025

INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN

Jul 01, 2025
pulisher
Jul 01, 2025

(INMB) Proactive Strategies - news.stocktradersdaily.com

Jul 01, 2025
pulisher
Jul 01, 2025

INmune Bio Shares Fall After Downgrade From BTIG Research - MarketScreener

Jul 01, 2025
pulisher
Jul 01, 2025

INmune Bio Shares Plunge After Alzheimer's Trial Misses Target - Finimize

Jul 01, 2025
pulisher
Jul 01, 2025

INmune Bio (INMB) Faces Significant Downgrade by Scotiabank | INMB Stock News - GuruFocus

Jul 01, 2025
pulisher
Jul 01, 2025

A Drug-Trial Stock Sale - Bloomberg.com

Jul 01, 2025
pulisher
Jun 30, 2025

INmune Bio stock downgraded by Raymond James after Alzheimer’s trial miss - Investing.com Australia

Jun 30, 2025
pulisher
Jun 30, 2025

Inmune Bio Secures $18.9 Million in Stock Offering - TipRanks

Jun 30, 2025
pulisher
Jun 30, 2025

Clinical-Stage Biotech INmune Bio Secures $19M Through Strategic Share Offering - Stock Titan

Jun 30, 2025
pulisher
Jun 30, 2025

Raymond James Downgrades INmune Bio to Market Perform From Outperform; Shares Fall - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Inmune Bio’s Phase 2 Trial Shows Promise in Alzheimer’s - TipRanks

Jun 30, 2025
pulisher
Jun 30, 2025

INmune Bio shares tumble as Alzheimer’s drug falls short in mid-stage trial - Proactive Investors

Jun 30, 2025
pulisher
Jun 30, 2025

INmune Bio's XPro: A Missed Milestone or a Hidden Gem in Alzheimer's Drug Development? - AInvest

Jun 30, 2025
pulisher
Jun 30, 2025

INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial By Stocktwits - Investing.com India

Jun 30, 2025

Inmune Bio Inc (INMB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
大文字化:     |  ボリューム (24 時間):